| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
GCB-27b (1-1000 nM; 72 hours) effectively stimulated the production of Th1 cytokines in C57BL/6 mouse spleen cells in vitro, and no cytotoxicity was observed [1]. GCB-27b (100 nM; 2-24 hours) formed a more stable and durable complex with CD1d on mouse bone marrow-derived dendritic cells (BMDC) in vitro, and its surface presentation level was significantly enhanced compared with αGalCer at 12, 18 and 24 hours after incubation [1]. GCB-27b (24 hours) effectively induced Th1 activation in human peripheral blood mononuclear cell (PBMC)-derived NKT cells in vitro, and the frequency of IFN-γ+ cells was 2 times higher than that of αGalCer [1]. GCB-27b showed higher computational binding affinity to human and mouse CD1d than αGalCer, with a docking score of 20 for both, which is attributed to its optimized hydrophobic interactions in the CD1d A' pocket [1].
|
|---|---|
| ln Vivo |
In BALB/c mice, GCB-27b (2.33 nmol per mouse; intraperitoneal injection; single dose) induced serum IFN-γ levels 10.5 times higher than αGalCer, while IL-4 levels were similar to αGalCer, indicating that it has strong Th1-type immune activity [1]. In C57BL/6 mice, GCB-27b (2.33 nmol per mouse; intraperitoneal injection; single dose) effectively activated splenic dendritic cells (by increasing the expression of CD80 and CD86) and NK cells (by increasing the production of IFN-γ), indicating that it has strong innate immunostimulatory effects [1]. GCB-27b (0.58 nmol per mouse; intraperitoneal injection; single dose) reduced the number of B16-F10 melanoma lung metastatic nodules in C57BL/6 mice by 88% compared to αGalCer, driven by a strong Th1-biased cytokine response [1].
|
| Animal Protocol |
Animal/Disease Models:BALB/c (n=5)[1]
Doses: 2.33 nmol per mouse Route of Administration: Intraperitoneal injection; single dose Experimental Results: Serum IFN-γ levels increased 10.5-fold at 24 hours post-injection compared to αGalCer. IL-4 levels at 2 hours post-injection were comparable to those induced by αGalCer. IL-4 levels peaked at 2 hours and then decreased, while IFN-γ levels peaked at 24 hours and then decreased, consistent with strong Th1-biased activity. Animal/Disease Models:C57BL/6 (n=3)[1] Doses: 2.33 nmol per mouse Route of Administration: Intraperitoneal injection; single dose Experimental Results: Compared with αGalCer, this product significantly increased the mean fluorescence intensity (MFI) of CD80 and CD86 on CD11c+ dendritic cells (DCs). The proportion of IFN-γ+ NK cells in the spleen increased to 17.6%, significantly higher than that induced by αGalCer. Animal/Disease Models:C57BL/6 (n=6; melanoma lung metastasis model)[1] Doses: 0.58 nmol per mouse Route of Administration: Intraperitoneal injection; single dose Experimental Results: Compared with αGalCer, this study significantly increased serum IFN-γ levels (measured 24 hours after injection), and IL-4 levels (measured 2 hours after injection) were comparable to those induced by αGalCer. Compared with the αGalCer treatment group, the number of lung metastatic nodules was reduced by 88%, and H&E staining confirmed that lung metastasis was almost completely suppressed. |
| References |
| Molecular Formula |
C52H95NO10
|
|---|---|
| Molecular Weight |
894.31
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O[C@H]1[C@@H](CO)O[C@H](OC[C@H](NC(CC2=CC=C(OCC(CCCCCCCCC)CCCCCCCCC)C=C2)=O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)[C@H](O)[C@H]1O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1182 mL | 5.5909 mL | 11.1818 mL | |
| 5 mM | 0.2236 mL | 1.1182 mL | 2.2364 mL | |
| 10 mM | 0.1118 mL | 0.5591 mL | 1.1182 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
